US 12,168,652 B2
Neuromuscular blocking agents
George R. Kracke, Columbia, MO (US); Lalit N. Goswami, Columbia, MO (US); Marion F Hawthorne, Columbia, MO (US); and Satish S. Jalisatgi, Columbia, MO (US)
Assigned to The Curators of the University of Missouri, Columbia, MO (US)
Appl. No. 15/733,705
Filed by The Curators of the University of Missouri, Columbia, MO (US)
PCT Filed Mar. 27, 2019, PCT No. PCT/US2019/024386
§ 371(c)(1), (2) Date Sep. 30, 2020,
PCT Pub. No. WO2019/191301, PCT Pub. Date Oct. 3, 2019.
Claims priority of provisional application 62/650,702, filed on Mar. 30, 2018.
Prior Publication US 2021/0047289 A1, Feb. 18, 2021
Int. Cl. C07D 401/08 (2006.01); A61P 21/00 (2006.01); C07C 211/63 (2006.01)
CPC C07D 401/08 (2013.01) [A61P 21/00 (2018.01); C07C 211/63 (2013.01)] 2 Claims
 
1. A closo-carborane compound of Formula II, III, or IV, or a pharmaceutically acceptable salt thereof:
a)

OG Complex Work Unit Chemistry
wherein:
are the carbon atoms in the closo-carborane;
and wherein R and A are defined by one of the following:
(i) each R is a branched or unbranched C2 to C10 alkyl group and each A is an alkyl ammonium; or
(ii) each R is a branched or unbranched C4 to C10 alkyl group and each A is a cationic functional group independently selected from the group consisting of amine, ammonium, ether, alcohol, oxonium, sulfide, thiol, sulfonium, phosphane, phosphine, phosphonium, and combinations thereof, wherein at least one counter-ion is present for the cationic functional group.